Stay updated with breaking news from Clinical Proof. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS NO. 596/2014 AS IT FORMS...
Avacta appoints new Chief Executive Officer Christina Coughlin, MD PhD Clinical proof-of-concept demonstrated for Avacta's lead programme AVA6000 and proof-of-mechanism for the...
Medical Director, Oncology - Early Development in Full time, Director, Biomedicine with Adveritas - F. Hoffmann la Roche. Apply Today.
Second patient scheduled for implantation with NVD-003 in June 2023 Pivotal trial is expected to begin in the second half of 2024* Novadip Biosciences SA ("Novadip" or "the Company"), a clinical-stage
In a small phase 2 trial, subcutaneous exenatide led to a significant reduction in intracranial pressure and number of monthly headaches in patients with IIH.